These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Lau KH; Kumar A; Yang IH; Nowak RJ Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302 [TBL] [Abstract][Full Text] [Related]
7. Myasthenia gravis exacerbation associated with pembrolizumab. Zhu J; Li Y Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533 [No Abstract] [Full Text] [Related]
8. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy. Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313 [TBL] [Abstract][Full Text] [Related]
9. Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma. Pottier C; El Habnouni C; Kervarrec T; Beltran S; Samimi M Ann Dermatol Venereol; 2022 Jun; 149(2):142-145. PubMed ID: 35190214 [No Abstract] [Full Text] [Related]
11. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772 [No Abstract] [Full Text] [Related]
12. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
14. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Alnahhas I; Wong J Muscle Nerve; 2017 Jun; 55(6):E25-E26. PubMed ID: 27935080 [No Abstract] [Full Text] [Related]
15. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Nguyen BH; Kuo J; Budiman A; Christie H; Ali S Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909 [TBL] [Abstract][Full Text] [Related]
17. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638 [TBL] [Abstract][Full Text] [Related]
18. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study. Vissing J; O'Brien F; Wang JJ; Howard JF Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239 [No Abstract] [Full Text] [Related]
19. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT; Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051 [TBL] [Abstract][Full Text] [Related]
20. Eculizumab: a treatment option for myasthenia gravis? Gilhus NE Lancet Neurol; 2017 Dec; 16(12):947-948. PubMed ID: 29066164 [No Abstract] [Full Text] [Related] [Next] [New Search]